Volume 17, Issue 5 pp. 762-765
MASTER CASE PRESENTATION

Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy

Francesca Negosanti MD

Francesca Negosanti MD

Centro Dermatologico, Bologna, Italy

Search for more papers by this author
Vera Tengattini MD

Corresponding Author

Vera Tengattini MD

Division of Dermatology, Department of Specialized, Clinical and Experimental Medicine, University of Bologna, Bologna, Italy

Correspondence: Vera Tengattini, Division of Dermatology, University of Bologna, Via Massarenti 1, 40138 Bologna, Italy ([email protected]).

Search for more papers by this author
Carlotta Gurioli MD

Carlotta Gurioli MD

Division of Dermatology, Department of Specialized, Clinical and Experimental Medicine, University of Bologna, Bologna, Italy

Search for more papers by this author
Iria Neri MD

Iria Neri MD

Division of Dermatology, Department of Specialized, Clinical and Experimental Medicine, University of Bologna, Bologna, Italy

Search for more papers by this author
First published: 19 August 2018
Citations: 4

Summary

Background

Tuberous sclerosis is an autosomal dominant genodermatosis characterized by nonmalignant hamartomas in multiple organs. Facial angiofibromas are most commonly located on the face and have the potential to cause disfigurement. Facial disfigurement negatively affects the quality of life of patients and their families, often leading to negative psychosocial outcomes. Nowadays there are no treatment guidelines for facial angiofibromas but due to the progressive nature of facial angiofibromas a safe technique offering good results is needed.

Objective and Results

We report the case of a 40-year-old female affected by tuberous sclerosis, whose facial angiofibromas were satisfactorily treated by rapamycin 0.05% ointment, and a combined laser therapy.

CONFLICT OF INTEREST

The authors report no declaration of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.